ReachMD

07/12/2025

There’s only 1 day left to sign up for our live symposium on acromegaly care!

Don’t miss out—claim your spot now: https://ow.ly/Rqhe50VU7G2

Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and...

07/11/2025

FSGS remains a challenging, heterogeneous disease with limited approved treatment options—and often delayed diagnosis.

In this CME activity, Drs. Howard Trachtman and Kenneth Lieberman examine the complexity of managing FSGS and highlight strategies to improve patient outcomes.

Key takeaways from the discussion include:

🔹 Early signs matter. Subtle findings like elevated blood pressure and unrecognized proteinuria can delay diagnosis and intervention. Early identification is key to preserving kidney function.

🔹 Proteinuria is central. Lowering proteinuria remains the most reliable therapeutic goal and is strongly associated with improved outcomes—regardless of patient age or disease subtype.

🔹 Diagnosis is evolving. Histology alone is no longer enough. Genetic testing, particularly in Black patients with suspected FSGS, is becoming increasingly relevant to guide treatment decisions.

🔹 Treatment is still empirical. With no FDA-approved therapies, current management often relies on steroids, CNIs, and anti-RAS therapy. Sparsentan shows promise in clinical trials, but further evidence is needed.

🔹 Clinical trials are crucial. Advancing our understanding of FSGS depends on clinician participation in research and responsiveness to patient-reported outcomes.

Engage in this expert-led conversation to sharpen your approach to diagnosis, monitoring, and treatment of FSGS: https://ow.ly/LP6c50Wn6v1

Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the...

07/10/2025

Virtual learning kept us connected—but there’s nothing like being in the room.

This year, returns to an in-person format for the first time in five years.

Join us September 20 in NYC for face-to-face collaboration, clinical insights, and the shared energy that only live events deliver.

Reserve your spot: https://ow.ly/W6kv50WnJh2

07/09/2025

How does sparsentan compare to irbesartan in patients with FSGS?

Drs. Trachtman and Lieberman discuss findings from the and trials—both randomized, double-blind studies that evaluated sparsentan versus irbesartan.

In DUET, 25% of patients on sparsentan reached the partial remission endpoint vs. just 9% on irbesartan.

DUPLEX, a longer phase 3 study with nearly 400 patients, confirmed these trends at the 2-year mark with sustained reductions in proteinuria and numerically less eGFR decline. Subset analyses, including pediatric and genetic cohorts, showed consistent proteinuria reduction across groups.

Explore how clinical trial data are shaping the treatment landscape for FSGS: https://ow.ly/rmyF50Wn4SC

07/07/2025

As our understanding of deepens, so does our responsibility to rationalize therapy. The integration of novel agents into standard regimens must be strategic—not overwhelming.

One such promising candidate is , which uniquely blocks both endothelin and angiotensin II pathways. Evidence from The Mount Sinai Hospital suggests that this dual blockade may enhance renal protection by targeting synergistic pathways.

Meanwhile, Dr. Kenneth Lieberman reminds us that remains a central biomarker. Its reduction is not only a clinical goal but a surrogate for improved long-term outcomes.

Key Takeaways:

1️⃣ Minimize polypharmacy
2️⃣ Monitor proteinuria closely
3️⃣ Watch sparsentan in FSGS

Hear the full discussion: https://ow.ly/sSMg50WlIV5

07/06/2025

We’re only 1 week away from our acromegaly symposium!

Want to join? Sign up here: https://ow.ly/K3tk50VU7CM

Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and...

07/03/2025

Delayed diagnosis of endometriosis is all too common—patients often wait 3 to 5 years and see multiple providers before receiving clarity.

On September 20, we’ll explore the clinical signs, referral criteria, and treatment pathways to help providers navigate this complex condition.

Register to join the full session at : https://ow.ly/hXWa50WkkEb

07/02/2025

Focal Segmental Glomerulosclerosis (FSGS) is a leading cause of kidney failure worldwide, yet no approved treatments exist today.

Early detection can change the game.

Drs. Trachtman and Lieberman explore the evolving treatment landscape, with sparsentan emerging as a potential game-changer thanks to its dual blockade of endothelin and angiotensin II.

Key Takeaways:

1️⃣ Early detection = better outcomes. Elevated BP or proteinuria? Don’t ignore it.
2️⃣ Lowering proteinuria is the goal. It’s the best predictor of long-term kidney health.
3️⃣ Clinically meaningful low proteinuria thresholds and partial and complete remission definitions were achieved earlier and more often with sparsenatn vs irbesartan in the DUPLEX phase 3 study.

Let’s push for better, targeted therapies—and listen to the patient voice: https://ow.ly/tNi950WjTAS

07/01/2025

Neuropsychiatric symptoms in are often the first signs but frequently missed. Learn how to recognize and manage them in this upcoming live symposium.

Register now: https://ow.ly/LYgo50WaZ9u

Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD...

06/27/2025

In our latest CME episode, Dr. Kenneth Lieberman emphasizes the clinical urgency of identifying and reducing proteinuria in FSGS management.

Hear more from Dr. Lieberman and Dr. Howard Trachtman as they discuss evidence-based strategies, pediatric perspectives, and the evolving treatment landscape for FSGS—including where sparsentan may fit in.

Tune in: https://ow.ly/4FXw50WfGJZ

Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the...

06/27/2025

What if PTSD treatment could go beyond symptom relief—and help retrain the brain?

In this expert discussion, Drs. Joseph F. Goldberg and Roger McIntyre explore emerging therapies that target the biology of fear and trauma: from monoaminergic modulation to neuroplasticity-enhancing agents like NMDA antagonists and psychedelics.

Start learning now: https://ow.ly/HZ6850WeGXK

Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a...

06/26/2025

A thought leader in contraception and menopause management, Dr. Anita Nelson brings decades of clinical experience, research, and teaching to the stage. Her work has shaped standards in practice across the country.

Don’t miss your chance to learn from Dr. Nelson and a powerhouse lineup at , happening September 20 in NYC. continues to evolve—are you up to date?

Details and registration: https://ow.ly/JbSC50WfIfy